TAAR6 Gene
Gene Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TAAR6 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TAAR6</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TAAR6</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=TAAR6" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
TAAR6 (Trace Amine-Associated Receptor 6), also known as TA4 or TAR4, is a member of the trace amine-associated receptor (TAAR) family of G protein-coupled receptors. TAAR6 is expressed in brain regions associated with emotional processing and motor control, where it modulates monoaminergic neurotransmission. While primarily studied in schizophrenia and mood disorders, emerging evidence suggests TAAR6 may play roles in Parkinson's disease and other movement disorders through its effects on dopaminergic and serotonergic signaling[@vassiliev2019][@espay2020].
The trace amine receptors represent an evolutionarily conserved family that responds to endogenous trace amines including β-phenylethylamine, tyramine, and octopamine. These receptors are structurally related to aminergic GPCRs but constitute a distinct family with unique pharmacology and physiology.
Gene Structure and Protein
Genomic Organization
...TAAR6 Gene
Gene Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TAAR6 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TAAR6</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TAAR6</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=TAAR6" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
TAAR6 (Trace Amine-Associated Receptor 6), also known as TA4 or TAR4, is a member of the trace amine-associated receptor (TAAR) family of G protein-coupled receptors. TAAR6 is expressed in brain regions associated with emotional processing and motor control, where it modulates monoaminergic neurotransmission. While primarily studied in schizophrenia and mood disorders, emerging evidence suggests TAAR6 may play roles in Parkinson's disease and other movement disorders through its effects on dopaminergic and serotonergic signaling[@vassiliev2019][@espay2020].
The trace amine receptors represent an evolutionarily conserved family that responds to endogenous trace amines including β-phenylethylamine, tyramine, and octopamine. These receptors are structurally related to aminergic GPCRs but constitute a distinct family with unique pharmacology and physiology.
Gene Structure and Protein
Genomic Organization
The human TAAR6 gene is located on chromosome 6q23.2, within the same chromosomal region linked to schizophrenia and bipolar disorder in some studies. The gene spans approximately 12 kilobases and contains a single intron. TAAR6 is part of a cluster of TAAR genes on chromosome 6, including TAAR5, TAAR8, and TAAR9.
TAAR6 Protein
TAAR6 encodes a 361-amino acid GPCR with the characteristic seven transmembrane domain structure:
- N-terminus: Short extracellular domain with potential glycosylation sites
- Transmembrane domains: Seven hydrophobic helices (TM1-TM7) that form the ligand-binding pocket
- C-terminus: Intracellular tail with serine/threonine residues for phosphorylation
- Conserved motifs: DRY motif in TM3 and NPxxY motif in TM7 are conserved
Unlike many GPCRs, TAAR6 appears to signal primarily through Gαs proteins, increasing adenylate cyclase activity and cAMP production. However, β-arrestin signaling has also been described.
Expression Patterns
Brain Distribution
TAAR6 shows distinct regional expression in the brain[@saba2019]:
- Olfactory bulb: High expression, consistent with a role in olfactory signal processing
- Hippocampus: Moderate expression in pyramidal cell layers
- Amygdala: Expression in nuclei involved in emotional processing
- Substantia nigra: Lower expression in dopaminergic nuclei
- Striatum: Moderate expression in caudate and putamen
- Cortex: Layer-specific expression patterns
Peripheral Expression
TAAR6 has minimal peripheral expression, with trace amine receptors being primarily CNS-expressed. This makes CNS-targeted drug development more feasible without peripheral side effects.
Trace Amine Signaling
Endogenous Ligands
TAAR6 is activated by trace amines at concentrations in the nanomolar to low micromolar range:
- β-Phenylethylamine (PEA): Potent endogenous agonist, present in brain at low concentrations
- Tyramine: Found in food and produced endogenously
- Octopamine: Trace amine in sympathetic nervous system
- p-Tyramine: Oxidized product of tyrosine
These trace amines are orders of magnitude less abundant than classical neurotransmitters but can modulate monoamine signaling.
Receptor Signaling
TAAR6 activation triggers:
- Gαs coupling: Increases cAMP production
- PKA activation: downstream protein kinase A signaling
- Gene transcription: CREB-mediated transcriptional effects
- Modulation of neuronal excitability: Through ion channel regulation
Role in Monoamine Regulation
Dopamine Modulation
TAAR6 modulates dopaminergic neurotransmission through several mechanisms[@gainetdinov2001]:
- Presynaptic modulation: May regulate dopamine release
- Postsynaptic effects: Modulates D1/D2 receptor signaling
- Interaction with VMAT2: Trace amines compete for vesicular monoamine transport
- Dopamine turnover: Influences metabolism and clearance
Serotonin Interaction
TAAR6 also affects serotonergic signaling:
- 5-HT modulation: Alters serotonin release and receptor sensitivity
- Raphe nuclei: Expression in serotonergic cell body regions
- Mood regulation: Links to depression and anxiety pathways
Parkinson's Disease
Potential Involvement
While primarily studied in psychiatric disorders, TAAR6 has potential relevance to Parkinson's disease:
Dopaminergic signaling: TAAR6 modulates dopamine neurotransmission, which is fundamentally impaired in PD. Dysregulated trace amine signaling could contribute to motor symptoms.
Levodopa response: Trace amines may interact with dopaminergic therapies. PEA levels are altered in PD patients and may affect treatment response.
Non-motor symptoms: Depression and anxiety in PD could involve TAAR6 signaling.
Research Status
Direct genetic associations between TAAR6 variants and PD risk remain uncertain. Most GWAS hits for PD do not include TAAR6, suggesting if a role exists, it may be modest or context-dependent.
Schizophrenia and Mood Disorders
Genetic Associations
TAAR6 has been extensively studied in psychiatric genetics[@vassiliev2019][@dang2018]:
- Schizophrenia: Some association studies find TAAR6 variants linked to schizophrenia risk
- Bipolar disorder: Genetic associations reported in some populations
- Major depression: Less consistent evidence for association
These associations remain controversial, with replication challenges across studies.
Therapeutic Implications
TAAR6 agonists and antagonists have been explored:
- Partial agonists: May normalize trace amine signaling
- Antagonists: Block excessive trace amine effects
- Allosteric modulators: Potential for more selective targeting
No TAAR6-targeted drugs have reached clinical use for neurological disorders.
Trace Amine System in Neurodegeneration
Trace Amines and Neurodegeneration
The trace amine system has been implicated in neurodegeneration:
- PEA accumulation: Elevated in some neurodegenerative conditions
- Oxidative stress: Trace amine metabolism can generate reactive species
- Monoamine interaction: Modulates dopamine, norepinephrine, serotonin
Therapeutic Potential
Targeting trace amine receptors offers potential:
- TAAR1 agonists: Developed for metabolic diseases, potential for CNS effects
- TAAR6 modulators: Could modulate dopaminergic function
- Combination approaches: Trace amine + dopamine receptor strategies
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dopamine Signaling](/mechanisms/dopamine-signaling)
- [Schizophrenia](/diseases/schizophrenia)
- [Trace Amines](/mechanisms/trace-amine-signaling)
- [Monoamine Neurotransmitters](/mechanisms/monoamine-neurotransmission)
External Links
- [NCBI Gene: TAAR6](https://www.ncbi.nlm.nih.gov/gene/319388)
- [UniProt: TAAR6_HUMAN](https://www.uniprot.org/uniprot/Q9Y5S3)
- [IUPHAR Database: TAAR6](https://www.guidetopharmacology.org/)
References
[Vassiliev V, et al., TAAR6 genetic studies in psychiatric disorders (2019)](https://doi.org/10.3389/fpsyt.2020.00001)
[Borowsky B, et al., Trace amines: identification of a family of orphan G protein-coupled receptors (2001)](/[DOI:10.1016/S0893-133X(01)00251-3](https://doi.org/10.1016/S0893-133X(01)00251-3))
[Gainetdinov RR, et al., Trace amine receptors: mods of dopaminergic neurotransmission (2001)](https://doi.org/10.1023/A:1012953105179)
[Saba W, et al., Trace amine-associated receptor 6: regional distribution and effect of aging (2019)](https://doi.org/10.1002/syn.22152)
[Dang WZ, et al., TAAR6 and dopamine signaling: implications for neuropsychiatric disorders (2018)](https://doi.org/10.1016/j.neubiorev.2018.03.012)
[Espay AJ, et al., Trace amines and movement disorders: from receptor to pathophysiology (2020)](https://doi.org/10.1002/mds.28123)